Z-GLY-PRO-ARG-4MBNA COH
Need Assistance?
  • US & Canada:
    +
  • UK: +

Z-GLY-PRO-ARG-4MBNA COH

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Z-GLY-PRO-ARG-4MBNA COH is a thrombin substrate which has been modeled after a thrombin cleavage site in human fibrinogen. It can be used for a sensitive assay of antithrombin III activity.

Category
Others
Catalog number
BAT-015570
CAS number
66647-41-4
Molecular Formula
C32H39N7O6
Molecular Weight
617.71
Z-GLY-PRO-ARG-4MBNA COH
IUPAC Name
benzyl N-[2-[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-1-[(4-methoxynaphthalen-2-yl)amino]-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]carbamate
Synonyms
Z-Gly-Pro-Arg-MNA; Z-Gly-Pro-Arg-4-methoxy-2-naphthylamide; Z-Gly-Pro-Arg-4MβNA
Appearance
Beige Powder
Sequence
Cbz-Gly-Pro-Arg-MNA
InChI
InChI=1S/C32H39N7O6/c1-44-27-18-23(17-22-11-5-6-12-24(22)27)37-29(41)25(13-7-15-35-31(33)34)38-30(42)26-14-8-16-39(26)28(40)19-36-32(43)45-20-21-9-3-2-4-10-21/h2-6,9-12,17-18,25-26H,7-8,13-16,19-20H2,1H3,(H,36,43)(H,37,41)(H,38,42)(H4,33,34,35)/t25-,26-/m0/s1
InChI Key
GRFKZYIOWWFSLU-UIOOFZCWSA-N
Canonical SMILES
COC1=CC(=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3CCCN3C(=O)CNC(=O)OCC4=CC=CC=C4
1. Retraction: CoH-catalyzed radical hydroalkylation of alkenes with 1,3-dicarbonyls
Meihui Guan, Huanran Miao, Tao Qin, Ge Zhang, Qian Zhang Chem Commun (Camb). 2022 Nov 22;58(93):13023. doi: 10.1039/d2cc90405e.
Retraction of 'CoH-catalyzed radical hydroalkylation of alkenes with 1,3-dicarbonyls' by Meihui Guan et al., Chem. Commun., 2022, 58, 5265-5268, https://doi.org/10.1039/D2CC01382G.
2. What Is the Best Regimen for Ovarian Stimulation of Poor Responders in ART/IVF?
Zeev Blumenfeld Front Endocrinol (Lausanne). 2020 Apr 17;11:192. doi: 10.3389/fendo.2020.00192. eCollection 2020.
The infertile patients with aging ovaries-also sometimes referred to as impending premature ovarian insufficiency (POI), impending premature ovarian failure (POF), or poor ovarian responders (POR), constitute a significant and increasing bulk of the patients appealing to IVF/ART. Different causes have been cited in the literature, among the identified etiologies, including chromosomal and genetic etiology, metabolic, enzymatic, iatrogenic, toxic, autoimmune, and infectious causes. Although the most successful and ultimate treatment of POI/POF/POR patients is egg donation (ED), many, if not most, of these infertile women are reluctant to consent to ED upon the initial diagnostic interview, requesting alternative solutions despite the low odds for success. Despite anecdotal case reports, no unequivocal treatment proved to be successful for these patients in prospective randomized controlled trials. Nevertheless, the addition of growth hormone (GH) to ovarian stimulation in POR with GH deficiency may improve the results of controlled ovarian hyperstimulation (COH) and the IVF success. In patients with autoimmune etiology for POR/POI, the combination of glucocorticosteroids, pituitary-ovarian suppression, and COH may be successful in achieving the desired conception.
3. New hemodynamic criteria to separate classical orthostatic hypotension from vasovagal syncope
Maryam Ghariq, Fabian I Kerkhof, Robert H Reijntjes, Roland D Thijs, J Gert van Dijk Ann Clin Transl Neurol. 2021 Aug;8(8):1635-1645. doi: 10.1002/acn3.51412. Epub 2021 Jun 24.
Objective: To define and evaluate hemodynamic criteria to distinguish between classical orthostatic hypotension (cOH) and vasovagal syncope (VVS) in tilt table testing (TTT). Methods: Inclusion criteria for VVS were a history of VVS and tilt-induced syncope defined as a blood pressure (BP) decrease and electroencephalographic changes during syncope with complaint recognition. Criteria for cOH were a history of cOH and a BP decrease meeting published criteria. Clinical diagnoses were established prior to TTT. We assessed (1) whether the decrease of systolic BP accelerated, "convex," or decelerated, "concave"; (2) the time from head-up tilt to when BP reached one-half its maximal decrease; (3) the difference between baseline heart rate (HR) and HR at BP nadir. We calculated the diagnostic yield of optimized thresholds of these features and their combinations. Results: We included 82 VVS cases (40% men, median age 44 years) and 65 cOH cases (66% men, median age 70 years). BP decrease was concave in cOH in 79% and convex in VVS in 94% (p < 0.001). The time to reach half the BP decrease was shorter in cOH (median 34 sec, interquartile range (IQR) 19-98 sec) than in VVS (median 1571 sec, IQR 1381-1775 sec, p < 0.001). Mean HR increased by 11 ± 11 bpm in cOH and decreased by 20 ± 19 bpm in VVS (p < 0.001). When all three features pointed to VVS, sensitivity for VVS was 82% and specificity was 100%. When all three pointed to cOH, sensitivity for cOH was 71% and specificity was 100%. Interpretation: These new hemodynamic criteria reliably differentiate cOH from VVS.
Online Inquiry
Verification code
Inquiry Basket